Julie Autmizguine1,2,3, P Brian Smith4,5, Kristi Prather5, Catherine Bendel6, Girija Natarajan7, Margarita Bidegain4, David A Kaufman8, David J Burchfield9, Ashley S Ross10, Paresh Pandit11, Wiley A Schell12, Jamie Gao5, Daniel K Benjamin4,5. 1. Department of Pharmacology and Physiology, Université de Montréal, Montreal, Canada. 2. Department of Pediatrics, Université de Montréal, Montréal, Canada. 3. Research Center, CHU Ste-Justine, Montréal, Canada. 4. Department of Pediatrics, Duke University, Durham, NC, USA. 5. Duke Clinical Research Institute, Duke University, Durham, NC, USA. 6. University of Minnesota, Minneapolis, MN, USA. 7. Wayne State University, Detroit, MI, USA. 8. University of Virginia, Charlottesville, VA, USA. 9. University of Florida, Gainesville, FL, USA. 10. University of Arkansas for Medical Sciences, Little Rock, AR, USA. 11. Children's Hospital of Philadelphia at Vitua West Jersey Hospital Voorhees, Voorhees, NJ, USA. 12. Department of Medicine, Duke University, Durham, NC, USA.
Abstract
Objectives: Extremely premature infants are at high risk of developing invasive candidiasis; fluconazole prophylaxis is safe and effective for reducing invasive candidiasis in this population but further study is needed. We sought to better understand the effect of prophylactic fluconazole on a selection of fluconazole-resistant Candida species. Methods: We evaluated the susceptibility to fluconazole of Candida isolates from premature infants (<750 g birth weight) enrolled in a multicentre, randomized, placebo-controlled trial of fluconazole prophylaxis. Candida species were isolated through surveillance cultures at baseline (study day 0-7), period 1 (study day 8-28) and period 2 (study day 29-49). Fluconazole MICs were determined for all Candida isolates. Results: Three hundred and sixty-one infants received fluconazole (n = 188) or placebo (n = 173). After the baseline period, Candida colonization was significantly lower in the fluconazole group compared with placebo during periods 1 (5% versus 27%; P < 0.001) and 2 (3% versus 27%; P < 0.001). After the baseline period, two infants (1%) were colonized with at least one fluconazole-resistant Candida in each group. Median fluconazole MIC was similar in both treatment groups at baseline and period 1. However, in period 2, median MIC was higher in the fluconazole group compared with placebo (1.00 versus 0.50 mg/L, P = 0.01). There was no emergence of resistance observed and no patients developed invasive candidiasis with a resistant Candida isolate. Conclusions: Fluconazole prophylaxis decreased Candida albicans and 'non-albicans' Candida colonization and was associated with a slightly higher fluconazole MIC for colonizing Candida isolates.
RCT Entities:
Objectives: Extremely premature infants are at high risk of developing invasive candidiasis; fluconazole prophylaxis is safe and effective for reducing invasive candidiasis in this population but further study is needed. We sought to better understand the effect of prophylactic fluconazole on a selection of fluconazole-resistant Candida species. Methods: We evaluated the susceptibility to fluconazole of Candida isolates from premature infants (<750 g birth weight) enrolled in a multicentre, randomized, placebo-controlled trial of fluconazole prophylaxis. Candida species were isolated through surveillance cultures at baseline (study day 0-7), period 1 (study day 8-28) and period 2 (study day 29-49). Fluconazole MICs were determined for all Candida isolates. Results: Three hundred and sixty-one infants received fluconazole (n = 188) or placebo (n = 173). After the baseline period, Candida colonization was significantly lower in the fluconazole group compared with placebo during periods 1 (5% versus 27%; P < 0.001) and 2 (3% versus 27%; P < 0.001). After the baseline period, two infants (1%) were colonized with at least one fluconazole-resistant Candida in each group. Median fluconazole MIC was similar in both treatment groups at baseline and period 1. However, in period 2, median MIC was higher in the fluconazole group compared with placebo (1.00 versus 0.50 mg/L, P = 0.01). There was no emergence of resistance observed and no patients developed invasive candidiasis with a resistant Candida isolate. Conclusions: Fluconazole prophylaxis decreased Candida albicans and 'non-albicans' Candida colonization and was associated with a slightly higher fluconazole MIC for colonizing Candida isolates.
Authors: Daniel K Benjamin; Barbara J Stoll; Avory A Fanaroff; Scott A McDonald; William Oh; Rosemary D Higgins; Shahnaz Duara; Kenneth Poole; Abbot Laptook; Ronald Goldberg Journal: Pediatrics Date: 2006-01 Impact factor: 7.124
Authors: Emmi Sarvikivi; Outi Lyytikäinen; David R Soll; Claude Pujol; Michael A Pfaller; Malcolm Richardson; Pirkko Koukila-Kähkölä; Päivi Luukkainen; Harri Saxén Journal: J Clin Microbiol Date: 2005-06 Impact factor: 5.948
Authors: David Kaufman; Robert Boyle; Kevin C Hazen; James T Patrie; Melinda Robinson; Leigh B Grossman Journal: J Pediatr Date: 2005-08 Impact factor: 4.406
Authors: Daniel K Benjamin; Mark L Hudak; Shahnaz Duara; David A Randolph; Margarita Bidegain; Gratias T Mundakel; Girija Natarajan; David J Burchfield; Robert D White; Karen E Shattuck; Natalie Neu; Catherine M Bendel; M Roger Kim; Neil N Finer; Dan L Stewart; Antonio C Arrieta; Kelly C Wade; David A Kaufman; Paolo Manzoni; Kristi O Prather; Daniela Testoni; Katherine Y Berezny; P Brian Smith Journal: JAMA Date: 2014-05-07 Impact factor: 157.335
Authors: Jacqueline G Gerhart; Kevin M Watt; Andrea Edginton; Kelly C Wade; Sara N Salerno; Daniel K Benjamin; P Brian Smith; Christoph P Hornik; Michael Cohen-Wolkowiez; Shahnaz Duara; Ashley Ross; Karen Shattuck; Dan L Stewart; Natalie Neu; Daniel Gonzalez Journal: CPT Pharmacometrics Syst Pharmacol Date: 2019-05-22
Authors: Domenico Umberto De Rose; Sara Cairoli; Marco Dionisi; Alessandra Santisi; Luca Massenzi; Bianca Maria Goffredo; Carlo Dionisi-Vici; Andrea Dotta; Cinzia Auriti Journal: Int J Mol Sci Date: 2020-08-17 Impact factor: 5.923
Authors: Danielle da Nóbrega Alves; Alana Rodrigues Ferreira; Allana Brunna Sucupira Duarte; Ana Karoline Vieira Melo; Damião Pergentino de Sousa; Ricardo Dias de Castro Journal: Biomed Res Int Date: 2021-04-06 Impact factor: 3.411
Authors: M Bertolini; R Vazquez Munoz; L Archambault; S Shah; J G S Souza; R C Costa; A Thompson; Y Zhou; T Sobue; A Dongari-Bagtzoglou Journal: mBio Date: 2021-08-17 Impact factor: 7.867
Authors: Nicolas Lebouvier; Fabrice Pagniez; Young Min Na; Da Shi; Patricia Pinson; Mathieu Marchivie; Jean Guillon; Tarek Hakki; Rita Bernhardt; Sook Wah Yee; Claire Simons; Marie-Pierre Lézé; Rolf W Hartmann; Angélique Mularoni; Guillaume Le Baut; Isabelle Krimm; Ruben Abagyan; Patrice Le Pape; Marc Le Borgne Journal: Pharmaceuticals (Basel) Date: 2020-08-08